Study of Humoral Immunity against Coronavirus Infection COVID-19 in Vaccinated Individuals with Vaccines Available in the Republic of Belarus (Sputnik V (Gam-COVID-Vac), RF and Sinopharm (BBIBP-CorV), PRC)

Relevance. Many countries around the world are developing effective vaccines against SARS-CoV-2. The measure of the effectiveness of the vaccination process has traditionally been antibody production. The frequency and intensity of adverse reactions is also an important factor in making a decision regarding a vaccine. This study presents the results of the evaluation of the formation of humoral immunity and the occurrence of reactions in response to the administration of Sputnik V (Gam-COVID-Vac), RF, and Sinopharm (BBIBP-CorV), PRC. Aim. Analyze immunogenicity and reactogenicity of COVID-19 vaccines used in the Republic of Belarus (Sputnik V and Sinopharm). Materials and methods. Evaluation of postvaccination immune response by enzyme immunoassay and differential enzyme immunoassay for class G immunoglobulins to S- and N-proteins SARS-CoV-2. Blood plasma of the study participants was used as biological material. Blood sampling was performed 3 times: immediately before the first vaccine dose, on day 42, and 6 months after the first vaccine dose. To evaluate the frequency and intensity of postvaccination reactions, study participants were questioned. Results. At 42 days after administration of both vaccines, antibody levels are rising, with a significantly higher quantitative IgG count for the Sputnik V vaccine. This trend is also observed 6 months after the first dose of both vaccines, both among those previously infected with SARS-CoV-2 and those without a history of COVID-19. The comparison of Sputnik V and Sinopharm vaccine groups in terms of IgG (BAU/ml) levels to S- and N-proteins revealed a statistically significant difference in IgG levels to S-protein: the Sputnik V vaccine group had significantly higher IgG levels to S-protein than the Sinopharm vaccine group (p = 0.0000196). The incidence of adverse reactions in this study was 45%. All reactions noted were mild to moderate in severity. The most common were soreness and redness at the injection site, elevated body temperature, and a combination of several reactions. The increased body temperature after vaccination was more common among those vaccinated with the Sputnik V vaccine. Conclusion. Compared to Sinopharm, Sputnik V vaccine produces higher antibody level. Adverse reactions were observed in both vaccinated groups. However, significant statistical differences were found with regard to fever in the Sputnik V vaccine group, which occurred more frequently.

1. WHO Coronavirus (COVID-19) dashboard [Internet]. World Health Organization (WHO). Доступно на: https://covid19.who.int/ Ссылка активна на 5 апреля 2022.

2. Wong R.S.Y. COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects. The Malaysian Journal of Pathology. 2021. Vol. 43, N2. P. 203–217.

3. Argote P., Barham E., Zukerman Daly S., et al. The shot, the message, and the messenger: COVID-19 vaccine acceptance in Latin America // npj Vaccines. 2021. Vol. 6, P. 118. doi: 10.1038/s41541-021-00380-x

4. Strizovaa Z., Smetanovaa J., Bartunkovaa J., et al. Principles and Challenges in anti-COVID-19 Vaccine Development. International Archives of Allergy and Immunology. 2021. Vol. 1, P. 1–11.

5. Khan M., Adil S.F., Alkhathlan H.Z., et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far // Molecules. 2020. Vol. 26, N1. P. 39.

6. Jackson S.E., Paul E., Brown J., et al. Negative vaccine attitudes and intentions to vaccinate against Covid-19 in relation to smoking status: a population survey of UK adults // Nicotine & Tobacco Research. 2021. Vol. 23, N9. P. 1623–1628.

7. Basta N.E., Moodie E.M.M. on behalf of the VIPER (Vaccines, Infectious disease Prevention, and Epidemiology Research) Group COVID-19 Vaccine Development and Approvals Tracker Team. COVID-19 Vaccine Development and Approvals Tracker. Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4) (2020). https://covid19.trackvaccines.org/

8. Our World In Data, University of Oxford, UK https://ourworldindata.org/coronavirus/country/belarus

9. Loo K.Y., Letchumanan V., Ser H.L., et al. COVID-19: Insights into Potential Vaccines // Microorganisms. 2021. Vol. 9, N3. P. 605. doi: 10.3390/microorganisms9030605

10. Mao Q., Xu M., He Q., et al. COVID-19 vaccines: progress and understanding on quality control and evaluation // Signal Transduction and Targeted Therapy. 2021. N6. P. 199.

11. Kisby T., Yilmazer A., Kostarelos K. Reasons for success and lessons learnt from nanoscale vaccines against COVID-19. Nature Nanotechnology. 2021. Vol. 16, N8. P. 843–850.

12. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021. Vol. 397, N10275. P. 671–681.

13. Zahid M.N. Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study // Vaccines (Basel). 2021. Vol. 9, N11. P. 1369.

14. Houshmand B., Keyhan S.O., Fallahi H.R., et al. Vaccine-associated complications: a comparative multicenter evaluation among dental practitioners and dental students—which candidate vaccine is more safe in SARS COV II, Gam-COVID-Vac (Sputnik V), ChAdOx1 nCoV-19 (AstraZeneca), BBV152 (Covaxin), or BBIBP-CorV(Sinopharm)? // Maxillofacial Plastic and Reconstructive Surgery. 2022. Vol. 44, N1. P. 3.

15. Pourani M.R., Shahidi Dadras M., Salari M., et al. Cutaneous adverse events related to COVID-19 vaccines: A cross-sectional questionnaire-based study of 867 patients // Dermatologic Therapy. 2022. Vol. 35, N2. P. e15223.

16. Karimi N., Boostani R., Fatehi F., et al. Guillain-Barre Syndrome and COVID-19 Vaccine: A Report of Nine Patients. Basic Clinical Neuroscience. 2021. Vol. 12, N5. P. 703–710.

17. Petrović V., Vuković V., Marković M., et al. Early Effectiveness of Four SARS-CoV-2 Vaccines in Preventing COVID-19 among Adults Aged ≥60 Years in Vojvodina, Serbia. Vaccines. 2022. Vol. 10, N3. P. 389.

18. Dashdorj N.J., Wirz O.F., Röltgen K., et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia // Cell Host & Microbe. 2021. Vol. 29, N12. P. 1738–1743.e4.

19. Vokó Z., Kiss Z., Surján G., et al. Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary – the HUN-VE study. Clinical Microbiology and Infection. 2021. Vol. S1198-743X, N21. P. 00639.